Kodiak Sciences Inc. (KOD) Stock

Understand Kodiak Sciences Inc.: how it makes money

Kodiak Sciences develops and commercializes therapeutics for retinal diseases, with its lead program KSI-301 (an anti-VEGF antibody biopolymer) in Phase IIb/III studies, and it would need clinical success and regulatory approval to generate product revenue.

For a clinical-stage retinal biopharma like Kodiak, profit potential is structurally driven by whether late-stage trials of KSI-301 and related programs enroll on schedule and hit efficacy and safety endpoints, because reported revenue is 0.0B in the latest period.

Business quality (Weak): A clinical-stage retinal therapeutics company with clear trial progress metrics (enrollment and Week 48 efficacy and complication rates), but currently no reported revenue and a very large operating loss, so outcomes depend heavily on future study results.

Bull case

• Late-stage development progress for multiple retinal indications: KSI-301 is in Phase IIb/III study for wet age-related macular degeneration and is also being studied for diabetic macular edema, nave macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
• Trial metrics show efficacy versus sham for the Zenkuda arm: In the provided Week 48 data, 62.5% of Zenkuda-treated patients achieved a two-step diabetic retinopathy severity scale improvement, versus 3.3% in the sham-treated group.
• Complication risk appears reduced versus sham (through Week 48): The provided data show 85.0% risk reduction versus sham for sight-threatening diabetic retinopathy complications through Week 48.

Bear case

• No reported revenue in the latest period: The latest reported period shows revenue of 0.0B, which underscores that near-term financial results are not yet supported by product sales.
• Large operating losses: The latest reported operating margin is -3642.7%, reflecting substantial ongoing costs relative to revenue.
• Safety and tolerability still need ongoing confirmation: Even with provided adverse event rates (for example cataract adverse event rate in the study eye, Zenkuda-treated 2.3% versus sham-treated 1.6%), the long-term and broader safety profile remains subject to future trial results.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Iovance Biotherapeutics, Inc. (IOVA)
• Relay Therapeutics, Inc. (RLAY)
• Tarsus Pharmaceuticals, Inc. (TARS)
• Beam Therapeutics Inc. (BEAM)
• BioCryst Pharmaceuticals, Inc. (BCRX)
• ADMA Biologics, Inc. (ADMA)
• Hemab Therapeutics Holdings, Inc. (COAG)
• Vericel Corporation (VCEL)